Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Virology

• Publication date

  2016-02-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.03179-15PMID 26842479PMCID PMC4810548
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Faculty of 1000 evaluation for The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.

  2018cited by this paper
• Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.

  2015cited by this paper
• Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.

  2015cited by this paper
• Use of 1-4 interaction scaling factors to control the conformational equilibrium between α-helix and β-strand.

  2015cited by this paper
• Low-mass molecular dynamics simulation for configurational sampling enhancement: More evidence and theoretical explanation

  2015cited by this paper
• Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).

  2015cited by this paper
• BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

  2015cited by this paper
• The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

  2015cited by this paper
• Polarization diversity of human CD4+ stem cell memory T cells.

  2015cited by this paper
• Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy

  2015cited by this paper
• At least 10% shorter C-H bonds in cryogenic protein crystal structures than in current AMBER forcefields.

  2015cited by this paper
• Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations

  2015cited by this paper
• Activation and lysis of human CD4 cells latently infected with HIV-1

  2015cited by this paper
• Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

  2015cited by this paper
• Polarization diversity of human CD4+ stem cell memory T cells(審査報告)

  2015cited by this paper
• BLT humanized mice as a small animal model of HIV infection.

  2015cited by this paper
• IFI16 DNA Sensor Is Required for Death of Lymphoid CD4 T Cells Abortively Infected with HIV

  2014influential reference
• Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41.

  2014cited by this paper
• HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

  2014cited by this paper
• Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

  2014cited by this paper
• Correction to Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation [Journal of Cell Biology, 206, 7, (2014), 867-876]

  2014cited by this paper
• A primary CD4+ T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence

  2014cited by this paper
• Low-mass molecular dynamics simulation: a simple and generic technique to enhance configurational sampling.

  2014cited by this paper
• Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

  2014cited by this paper
• Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4+ memory T Cells

  2014influential reference
• Inactivation of the Human Papillomavirus E6 or E7 Gene in Cervical Carcinoma Cells by Using a Bacterial CRISPR/Cas RNA-Guided Endonuclease

  2014cited by this paper
• Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation

  2014influential reference
• Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.

  2014cited by this paper
• Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation

  2014cited by this paper
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

  2013cited by this paper
• HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration

  2013cited by this paper
• Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection

  2013influential reference
• Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies

  2013cited by this paper
• Altering cell death pathways as an approach to cure HIV infection

  2013cited by this paper
• The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies

  2013cited by this paper
• Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.

  2013cited by this paper
• An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients

  2013cited by this paper
• DRAM Triggers Lysosomal Membrane Permeabilization and Cell Death in CD4+ T Cells Infected with HIV

  2013cited by this paper
• Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

  2013cited by this paper
• The Presence of HIV-1 Tat Protein Second Exon Delays Fas Protein-mediated Apoptosis in CD4+ T Lymphocytes

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• Interleukin-7 promotes HIV persistence during antiretroviral therapy.

  2013cited by this paper
• Anti-apoptotic mechanisms of HIV: lessons and novel approaches to curing HIV

  2012cited by this paper
• Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.

  2012cited by this paper
• Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

  2012cited by this paper
• Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

  2012cited by this paper
• HIV: Shock and kill

  2012cited by this paper
• The HIV-1-Specific Protein Casp8p41 Induces Death of Infected Cells through Bax/Bak

  2011cited by this paper
• Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells*

  2011cited by this paper
• Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization

  2011cited by this paper
• Structural basis of RNA recognition and activation by innate immune receptor RIG-I

  2011cited by this paper
• Integrating diverse genomic data using gene sets

  2011cited by this paper
• Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics.

  2011cited by this paper
• Mechanisms of HIV-associated lymphocyte apoptosis: 2010

  2010cited by this paper
• Patients with Discordant Responses to Antiretroviral Therapy Have Impaired Killing of HIV-Infected T Cells

  2010cited by this paper
• DeathBase: a database on structure, evolution and function of proteins involved in apoptosis and other forms of cell death

  2010cited by this paper
• Differential expression analysis for sequence count data

  2010cited by this paper
• RIG-I-Mediated Antiviral Signaling Is Inhibited in HIV-1 Infection by a Protease-Mediated Sequestration of RIG-I

  2010influential reference
• Intracellular Casp8p41 content is inversely associated with CD4 T cell count.

  2010cited by this paper
• Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

  2009cited by this paper
• Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR.

  2009cited by this paper
• Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis*

  2009cited by this paper
• HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

  2009cited by this paper
• Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection

  2008cited by this paper
• Bcl-2 family proteins and cancer

  2008cited by this paper
• Apoptosis: controlled demolition at the cellular level

  2008cited by this paper
• HIV Protease Cleavage of Procaspase 8 is Necessary for Death of HIV-Infected Cells

  2008cited by this paper
• Infected Cell Killing by HIV-1 Protease Promotes NF-κB Dependent HIV-1 Replication

  2008cited by this paper
• Clustering Molecular Dynamics Trajectories: 1. Characterizing the Performance of Different Clustering Algorithms.

  2007cited by this paper
• Human Immunodeficiency Virus Type 1 Protease Cleaves Procaspase 8 In Vivo

  2007cited by this paper
• The CASBAH: a searchable database of caspase substrates

  2007cited by this paper
• A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers

  2006cited by this paper
• Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

  2005cited by this paper
• Epstein-Barr Virus Provides a New Paradigm: A Requirement for the Immediate Inhibition of Apoptosis

  2005cited by this paper
• Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G

  2005cited by this paper
• Trashing the genome: the role of nucleases during apoptosis

  2005cited by this paper
• T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis

  2004cited by this paper
• CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract

  2004cited by this paper
• Rapid Turnover of Effector–Memory CD4+ T Cells in Healthy Humans

  2004cited by this paper
• Resistance to apoptosis: mechanism for the development of HIV reservoirs.

  2003cited by this paper
• Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

  2003cited by this paper
• HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation

  2002cited by this paper
• HIV-1 Nef associated PAK and PI3-Kinases stimulate Akt-independent Bad-phosphorylation to induce anti-apoptotic signals

  2001cited by this paper
• KEGG: Kyoto Encyclopedia of Genes and Genomes

  2000cited by this paper
• Gene Ontology: tool for the unification of biology

  2000cited by this paper
• Mechanisms of HIV-associated lymphocyte apoptosis.

  2000cited by this paper
• Resistance to Apoptosis in HIV-Infected CD4+ T Lymphocytes Is Mediated by Macrophages: Role for Nef and Immune Activation in Viral Persistence1

  2000cited by this paper
• The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication

  1997cited by this paper
• Structural analysis of the adenovirus type 5 E1B 55-kilodalton-E4orf6 protein complex

  1997cited by this paper
• Heteronuclear Ribonucleoproteins C1 and C2, Components of the Spliceosome, Are Specific Targets of Interleukin 1β-converting Enzyme-like Proteases in Apoptosis*

  1996cited by this paper
• Fine mapping of 28S rRNA sites specifically cleaved in cells undergoing apoptosis

  1995cited by this paper
• Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes

  1995cited by this paper
• The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency

  1994cited by this paper
• Rapid reduction of mRNA coding for 2'-5'-oligoadenylate synthetase in rat pheochromocytoma PC12 cells during apoptosis.

  1994cited by this paper
• Control of programmed cell death by the baculovirus genes p35 and iap

  1994cited by this paper
• Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems

  1993cited by this paper
• The HIV-1 gag precursor is processed via two pathways: implications for cytotoxicity.

  1991cited by this paper
• Prevention of apoptosis by a baculovirus gene during infection of insect cells.

  1991cited by this paper
• Deletion of the gene encoding the adenovirus 5 early region 1b 21,000-molecular-weight polypeptide leads to degradation of viral and host cell DNA

  1984cited by this paper
• Molecular dynamics with coupling to an external bath

  1984cited by this paper

• Unraveling the root causes of HIV-1 persistence.

  2026cites this paper
• How Effective are Nanotechnology-Based Therapeutics to Treat Autoimmune Diseases

  2026cites this paper
• The effect of combining HIV latency reversal with inhibition of phosphoinositide-3 kinases or B-cell lymphoma-2 on the HIV reservoir

  2026cites this paper
• Cytotoxic CD4 T Cells: Dual Agents in HIV-1 Pathogenesis and Persistence

  2026cites this paper
• A novel antiviral strategy by disrupting the equilibrium of virus-host calcium homeostasis.

  2025cites this paper
• Resist to persist: resistance of the HIV reservoir to immune-mediated clearance

  2025cites this paper
• HIV-1 accessory protein Vpr possesses a cryptic p300-dependent transcription-promoting activity that is blocked by histone deacetylases in CD4+ T cells

  2025cites this paper
• Immune-mediated strategies to solving the HIV reservoir problem

  2025cites this paper
• A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients

  2025cites this paper
• Current treatment of HIV and prospects for cure

  2025cites this paper
• Venetoclax-induced degradation of VP8* lectin domain disrupts group A rotavirus replication.

  2025cites this paper
• Host-directed approaches in the pursuit of a cure for HIV.

  2025cites this paper
• Quantitative and Qualitative Distinctions between HIV-1 and SIV Reservoirs: Implications for HIV-1 Cure-Related Studies

  2024cites this paper
• Isotretinoin promotes elimination of translation-competent HIV latent reservoirs in CD4T cells

  2024cites this paper
• Microglia and macrophages alterations in the CNS during acute SIV infection: A single-cell analysis in rhesus macaques

  2024cites this paper
• Differential susceptibility of cells infected with defective and intact HIV proviruses to killing by obatoclax and other small molecules

  2024cites this paper
• Microglia and macrophages alterations in the CNS during acute SIV infection: a single-cell analysis in rhesus macaques

  2024cites this paper
• Emerging roles of senolytics/senomorphics in HIV-related co-morbidities.

  2024cites this paper
• CD4+ T cells with latent HIV-1 have reduced proliferative responses to T cell receptor stimulation

  2024cites this paper
• Small molecule inhibitors of transcriptional cyclin-dependent kinases impose HIV-1 latency, presenting “block and lock” treatment strategies

  2023cites this paper
• Clinical trials aimed at HIV cure or remission: new pathways and lessons learned

  2023cites this paper
• Bcl-2 Antagonist Obatoclax Reactivates Latent HIV-1 via the NF-κB Pathway and Induces Latent Reservoir Cell Apoptosis in Latently Infected Cells.

  2023cites this paper
• Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice

  2023cites this paper
• Advances in HIV therapeutics and cure strategies: findings obtained through non-human primate studies

  2023cites this paper
• Decrypting biological hallmarks of aging in people with HIV

  2023cites this paper
• HIV-1 release requires Nef-induced caspase activation

  2023cites this paper
• Biological ageing with HIV infection: evaluating the geroscience hypothesis

  2022cites this paper
• So Pathogenic or So What?—A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research

  2022cites this paper
• The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model

  2022cites this paper
• Prime, shock and kill: BCL-2 inhibition for HIV cure

  2022influential citation
• The role of latency reversal in HIV cure strategies

  2022cites this paper
• Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus

  2022cites this paper
• How to break free: HIV-1 escapes from innovative therapeutic approaches

  2022cites this paper
• Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections

  2022cites this paper
• Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV

  2022cites this paper
• The reservoir of latent HIV

  2022cites this paper
• The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation

  2022cites this paper
• Advances in HIV Eradication Strategies

  2022cites this paper
• Current strategies to induce selective killing of HIV‐1‐infected cells

  2022cites this paper
• Hide and seek: for HIV-infected CD4+ T cells, playing well comes with maturity.

  2022cites this paper
• Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.

  2021cites this paper
• Macrophage and neutrophil death programs differentially confer resistance to tuberculosis.

  2021cites this paper
• The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models

  2021cites this paper
• Lnc(ing)RNAs to the “shock and kill” strategy for HIV-1 cure

  2021cites this paper
• Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV.

  2021cites this paper
• Selective elimination of host cells harboring replication-competent human immunodeficiency virus reservoirs: a promising therapeutic strategy for HIV cure

  2021cites this paper
• A New Small-Molecule Compound, Q308, Silences Latent HIV-1 Provirus by Suppressing Tat- and FACT-Mediated Transcription

  2021cites this paper
• Fighting HIV-1 Persistence: At the Crossroads of “Shoc-K and B-Lock”

  2021cites this paper
• Reactivating latent HIV with PKC agonists induces resistance to apoptosis and is associated with phosphorylation and activation of BCL2

  2020cites this paper
• Mechanisms of Human Immunodeficiency Virus-Associated Lymphocyte Regulated Cell Death

  2020influential citation
• Block-And-Lock Strategies to Cure HIV Infection

  2020cites this paper
• BCL-2 antagonism sensitizes cytotoxic t cell-resistant hiv reservoirs to elimination ex vivo.

  2020cites this paper
• Reduce and Control: A Combinatorial Strategy for Achieving Sustained HIV Remissions in the Absence of Antiretroviral Therapy

  2020cites this paper
• Pathways towards human immunodeficiency virus elimination

  2020cites this paper
• Senotherapeutics and HIV-1 Persistence

  2020cites this paper
• Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4+ T cells ex vivo

  2020cites this paper
• Future approaches to clearing the latent human immunodeficiency virus reservoir: Beyond latency reversal

  2020cites this paper
• Immunological approaches to HIV cure.

  2020cites this paper
• Senotherapeutics for HIV and aging.

  2019cites this paper
• BCL-2 Antagonism Sensitizes CTL-Resistant HIV Reservoirs to Elimination Ex Vivo

  2019cites this paper
• HIV "shock and kill" therapy: In need of revision.

  2019cites this paper
• Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10–12 October 2018, Bethesda, MD, USA

  2019cites this paper
• Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation.

  2019cites this paper
• Current challenges and recent advances in the search for a cure for HIV

  2019cites this paper
• Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors

  2019cites this paper
• Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation

  2019cites this paper
• Clinical pharmacology in HIV cure research – what impact have we seen?

  2019cites this paper
• Barriers and strategies to achieve a cure for HIV

  2019cites this paper
• The Role of the BCL-2 Family of Proteins in HIV-1 Pathogenesis and Persistence

  2019cites this paper
• Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.

  2019cites this paper
• Antiretroviral treatment, government policy and economy of HIV/AIDS in Brazil: is it time for HIV cure in the country?

  2019cites this paper
• Have Cells Harboring the HIV Reservoir Been Immunoedited?

  2019cites this paper
• Between a shock and a hard place: challenges and developments in HIV latency reversal.

  2019cites this paper
• HIV-1 Elimination in Humanized Mice

  2019cites this paper
• HIV cure strategies: a complex approach for a complicated viral reservoir?

  2019cites this paper
• Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.

  2018influential citation
• An advanced BLT-humanized mouse model for extended HIV-1 cure studies

  2018cites this paper
• Systems analysis by mass cytometry identifies susceptibility of latent HIV-infected T cells to targeting of p38 and mTOR pathways

  2018cites this paper
• The TRAIL: TRAILshort Axis in HIV Immunopathology.

  2018cites this paper
• Allogeneic stem cell transplantation alone is unlikely to provide the HIV-1 cure

  2018cites this paper
• The proapoptotic, HIV protease generated Casp8p41 when bound and inactivated 1 by Bcl2, is degraded by the proteasome

  2018influential citation
• New insight into the mechanisms of achieving antiretroviral therapy-free HIV-1 control.

  2018cites this paper
• Barriers and strategies to achieve a cure for HIV.

  2018cites this paper
• Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment

  2018cites this paper
• Targeting the Latent Reservoir for HIV‐1

  2018cites this paper
• Peering into the HIV reservoir

  2018cites this paper
• Therapeutic manipulation of host cell death pathways to facilitate clearance of persistent viral infections

  2018cites this paper
• HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome

  2018influential citation
• Emerging Therapies in HIV Infection: Is the Immune Response the Answer?

  2018cites this paper
• Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection

  2017cites this paper
• Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation

  2017cites this paper
• Factors Associated with the Size of HIV DNA Reservoir

  2017cites this paper
• Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.

  2017cites this paper
• Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex vivo patient cells

  2017cites this paper
• The Multifaceted Contributions of Chromatin to HIV-1 Integration, Transcription, and Latency.

  2017cites this paper
• HIV-infected macrophages and microglia that survive acute infection become viral reservoirs by a mechanism involving Bim

  2017cites this paper
• Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins

  2017cites this paper
• Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition

  2017influential citation
• Cancer therapies in HIV cure research

  2017cites this paper
• Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus

  2016cites this paper